Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model
批准号:
10693929
负责人:
PATRICIA Leal DAHIA
金额:
$48.35万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-08 至 2026-08-31
关键词:
AddressAdrenal GlandsAggressive courseAreaBehaviorBiologicalBiological ModelsBiologyCDK4 geneCatecholaminesCellsClinicalClinical ManagementClinical TrialsDataDetectionDevelopmentDiagnosisDiseaseDrug ScreeningEarly DiagnosisEpitheliumExperimental DesignsExperimental ModelsFutureGeneticHumanIndividualInvestigationKnowledgeLow PrevalenceMalignant - descriptorMalignant NeoplasmsMalignant Paraganglionic NeoplasmMalignant PheochromocytomaMetastatic PheochromocytomaMethodsModelingMolecularMorphologic artifactsNeoplasm MetastasisNervous SystemNeural CrestNeuroendocrine TumorsOrganoidsOutcomeParaganglia structureParagangliomaPatient-Focused OutcomesPatientsPharmaceutical PreparationsPheochromocytomaPopulationPrimary NeoplasmPropertyRecurrenceResearchResourcesSurvival RateTestingTherapeuticTumor BiologyTumor Markersanticancer researchchemotherapyclinical applicationclinical heterogeneityclinical predictorsdesigndrug candidatedrug sensitivityeffective therapyhigh-throughput drug screeningimprovedinsightmolecular markerneuroendocrine cancernovelnovel therapeuticspluripotencypredict clinical outcomepredictive markertargeted agenttherapeutic evaluationtherapeutic targettranscriptometumortumor behaviortumor initiationtumor progressionwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This proposal responds to the provocative question PQ9: What methods can be developed to effectively
study small or rare populations relevant to cancer research? We will address this question by generating
organoid models of pheochromocytomas and paragangliomas (PPGL) to fill gaps in the mechanisms underlying
tumor behavior and in therapeutic opportunities. PPGLs are rare catecholamine-secreting, neural crest-derived
tumors originating from adrenal or extra adrenal paraganglia, respectively. Malignant PPGLs can only be
recognized after detection of metastases, implying a late diagnosis. Approximately 30-40% of paragangliomas,
and 10-15% of pheochromocytomas can develop metastases. In addition, PPGLs are clinically heterogeneous,
can be recurrent and invasive, even without metastasis, but predictors of clinical behavior are lacking. Treatment
options are currently limited, with modest effects on survival, and advances in this area are dampened by a
scarcity of research models. Therefore, there is a critical need for developing models to uncover biological
mechanisms that facilitate clinical outcome prediction and reveal molecular vulnerabilities which can be explored
for therapeutic purposes. Our preliminary data indicate that we can successfully generate PPGL organoids that
are amenable for drug screen. Our aims are: 1) to determine if PPGL organoids recapitulate features of the
parental tumor; 2) to leverage PPGL organoids to investigate outstanding biological questions, including the
existence of cell subtypes that may be related to tumor outcome, and 3) to utilize PPGL organoids for high-
throughput drug screening that uncover vulnerabilities for future therapeutic testing, including novel leads
suggested in our preliminary data. The proposed project will serve as a useful resource for designing future
studies to decode the cellular and molecular mechanisms underlying PPGL development and clinical
heterogeneity. Results from these studies may provide the groundwork for future testing of candidate drugs that
might have immediate clinical application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model
-
批准号:10818715
-
项目类别:
-
资助金额:$7.41万
-
财政年份:2021
-
负责人:PATRICIA Leal DAHIA
-
依托单位:
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model
-
批准号:10304615
-
项目类别:
-
资助金额:$52.54万
-
财政年份:2021
-
负责人:PATRICIA Leal DAHIA
-
依托单位:
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex
-
批准号:9311059
-
项目类别:
-
资助金额:$29.72万
-
财政年份:2017
-
负责人:PATRICIA Leal DAHIA
-
依托单位:
海外基金